The failure of a clinical trial often leads to a decrease in the stock price of a pharmaceutical company. In this case, Mersana Therapeutics' UPLIFT clinical trial did not meet its primary endpoint, which is likely causing investors to lose confidence in the company's ability to bring the drug to market, leading to a decrease in the stock price.